Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CES1 | P23141 | 5/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11705927 | 1.00 | FAAH (0.50) | FAAHCA2CES1CES2 | |
| SCHEMBL27407223 | 1.00 | FAAH (0.50) | FAAHCA2CES1CES2 | |
| SCHEMBL27654967 | 1.00 | FAAH (0.50) | FAAHCA2CES1CES2 | |
| SCHEMBL877452 | 0.98 | FAAH (0.46) | FAAHCA2CES1CES2 | |
| SCHEMBL17111324 | 0.91 | FAAH (0.38) | FAAHCA2 | |
| Fluoride SCHEMBL28306809 | 0.89 | FAAH (0.37) | FAAH | |
| SCHEMBL5903237 | 0.89 | FAAH (0.32) | FAAH | |
| SCHEMBL180676 | 0.89 | FAAH (0.32) | FAAH | |
| SCHEMBL263273 | 0.89 | FAAH (0.32) | FAAH | |
| SCHEMBL10359085 | 0.89 | FAAH (0.32) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595482-B2 | Linkage modified oligomeric compounds and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250368995-A1 | Linkage Modified Oligomeric Compounds and Uses Thereof | IONIS PHARMACEUTICALS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20240002851-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-11629348-B2 | Linkage modified oligomeric compounds and uses thereof | IONIS PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-4013767-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220186222-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| CN-114555621-A | Bond-modified oligomeric compounds and uses thereof | IONIS制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021030778-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595482-B2 | Linkage modified oligomeric compounds and uses thereof | NSUN2, FBL, DCLRE1B | FAAH 4835/4885CA2 2697/4885CES1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.